ROCO
4186
Market cap27mUSD
Jul 09, Last price
9.91TWD
1D
-1.88%
1Q
-1.39%
Jan 2017
-59.75%
IPO
-82.77%
Name
Taiwan Advance Bio-Pharmaceutical Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Taiwan Advance Bio-Pharmaceutical Inc. is a biotechnology enterprise with a substantial international presence, conducting operations across numerous countries such as China, Germany, the USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, and Pakistan, in addition to other global markets. Founded in 1989 and headquartered in New Taipei City, Taiwan, the company delivers a comprehensive array of products and services. Its offerings encompass diagnostic kits for ensuring food safety, alongside tailored customization services for ELISA, rapid, and chemical test kits, and expert consultation for setting up food safety laboratories. The firm also specializes in manufacturing both monoclonal and polyclonal antibody products. Furthermore, its portfolio includes rapid screening tests for illicit substances. It provides essential cell banking services for the secure preservation of both newborn and adult stem cells. The company also operates a dedicated drug testing facility, performing analyses on urine and hair samples to detect and identify drug abuse.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||